A new platinum-chromium stent for treating coronary disease has shown "excellent safety and effectiveness" in trials.

Boston Scientific Corporation today (May 20th) announced the 12-month results from its Platinum Small Vessel study for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium Stent System

The global study compared the stent with results achieved with its TAXUS Express Paclitaxel-Eluting Stent.

Ian T Meredith, professor of cardiology and medicine at Monash University in Australia, presented the findings at the EuroPCR Scientific Program in Paris.

"The Platinum Small Vessel data demonstrate exceptionally low rates of revascularisation, while reporting no myocardial infarction or stent thrombosis at one year in patients treated with the 2.25 mm PROMUS Element Stent," he said.

"These results are impressive, especially considering the small vessel diameter in this patient population."

The PROMUS Element Stent System, which received CE Mark approval and was launched in Europe in 2009, features an innovative platinum-chromium alloy designed to provide greater radial strength, exceptional deliverability and high visibility

Boston anticipates US FDA approval for the stent system by mid 2012.

Source:



PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study (20/05/11) 

© Adfero Ltd